贝伐珠-话题@MedSci

#贝伐珠#

101篇内容 | 2874人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954846, encodeId=01b519548466b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, objectType=article, longId=220775, objectId=a95d220e7530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a95d220e7530, replyNumber=0, likeNumber=85, createdTime=2021-12-22, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a95d220e7530, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a95d220e7530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954873, encodeId=ae1c19548e358, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？, objectType=article, longId=727345, objectId=af29e27345ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af29e27345ba, replyNumber=0, likeNumber=39, createdTime=2022-05-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af29e27345ba, moduleTitle=肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af29e27345ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954868, encodeId=b14119548688e, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=299336, objectId=5af529933624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5af529933624, replyNumber=0, likeNumber=110, createdTime=2023-01-09, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af529933624, moduleTitle=Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af529933624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954840, encodeId=14a519548401b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, objectType=article, longId=214989, objectId=b1e72149892f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1e72149892f, replyNumber=0, likeNumber=72, createdTime=2022-05-19, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1e72149892f, moduleTitle=Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1e72149892f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954854, encodeId=c9e1195485444, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=221028, objectId=979e22102878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979e22102878, replyNumber=0, likeNumber=62, createdTime=2022-06-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979e22102878, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979e22102878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954867, encodeId=86e6195486e3b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, objectType=article, longId=299129, objectId=bdd0299129f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd0299129f0, replyNumber=0, likeNumber=64, createdTime=2022-08-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd0299129f0, moduleTitle=BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd0299129f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954838, encodeId=56e01954838ec, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, objectType=article, longId=214192, objectId=a0972141922d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0972141922d, replyNumber=0, likeNumber=75, createdTime=2021-11-21, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0972141922d, moduleTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0972141922d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954851, encodeId=2715195485148, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”, objectType=article, longId=220784, objectId=5468220e84fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5468220e84fa, replyNumber=0, likeNumber=0, createdTime=2022-03-08, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5468220e84fa, moduleTitle=贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5468220e84fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954848, encodeId=f1f1195484837, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗在肺癌驱动基因阴性的治疗, objectType=article, longId=220747, objectId=11d1220e47cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11d1220e47cc, replyNumber=0, likeNumber=74, createdTime=2022-07-09, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11d1220e47cc, moduleTitle=贝伐珠单抗在肺癌驱动基因阴性的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11d1220e47cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954837, encodeId=ced4195483e3b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=64, createdTime=2021-07-22, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954856, encodeId=2d791954856f3, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, objectType=article, longId=221259, objectId=06bd221259a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bd221259a2, replyNumber=0, likeNumber=54, createdTime=2022-08-27, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bd221259a2, moduleTitle=直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06bd221259a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954858, encodeId=b81619548581e, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=84, createdTime=2022-05-24, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954845, encodeId=a0cc1954845cf, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, objectType=article, longId=220774, objectId=fa70220e7438, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa70220e7438, replyNumber=0, likeNumber=57, createdTime=2022-08-17, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa70220e7438, moduleTitle=贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa70220e7438)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954859, encodeId=23331954859c7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, objectType=article, longId=292033, objectId=0686292033a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0686292033a0, replyNumber=0, likeNumber=71, createdTime=2022-09-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0686292033a0, moduleTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0686292033a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954842, encodeId=c6631954842e5, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, objectType=article, longId=216300, objectId=4bad2163009e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bad2163009e, replyNumber=0, likeNumber=69, createdTime=2022-08-01, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bad2163009e, moduleTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bad2163009e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954841, encodeId=2ea21954841a4, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒, objectType=article, longId=215197, objectId=d41921519e47, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d41921519e47, replyNumber=0, likeNumber=90, createdTime=2021-09-18, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d41921519e47, moduleTitle=Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d41921519e47)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954839, encodeId=fbed195483924, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, objectType=article, longId=214763, objectId=e0a7214e632f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a7214e632f, replyNumber=0, likeNumber=64, createdTime=2022-01-28, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a7214e632f, moduleTitle=J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a7214e632f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954861, encodeId=7f7c195486125, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, objectType=article, longId=292266, objectId=82df292266f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82df292266f0, replyNumber=0, likeNumber=49, createdTime=2022-11-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82df292266f0, moduleTitle=J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82df292266f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954853, encodeId=731f19548534d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=祝贺贝伐珠单抗在中国新增两项适应证, objectType=article, longId=220986, objectId=b1b1220986e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b1220986e9, replyNumber=0, likeNumber=66, createdTime=2021-11-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b1220986e9, moduleTitle=祝贺贝伐珠单抗在中国新增两项适应证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1b1220986e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954836, encodeId=a5ea19548361b, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准, objectType=article, longId=213464, objectId=e1b42134644e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1b42134644e, replyNumber=0, likeNumber=62, createdTime=2021-12-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1b42134644e, moduleTitle=信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1b42134644e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐珠

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的疗效

2021-12-22

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

肺腺癌合并脑转移的病人，贝伐珠单抗怎么用比较好？

2022-05-20

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Front Oncol：III期临床研究XELAVIRI评估一线贝伐珠单抗为基础的续观治疗对比联合治疗转移性结直肠癌（mCRC）患者的疗效

2023-01-09

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Cancer Discov：阿替利珠单抗（atezolizumab）联合贝伐珠单抗（bevacizumab）治疗恶性腹膜间皮瘤（MPeM）的疗效

2022-05-19

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2022-06-02

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

BMC Cancer：评估每周低剂量贝伐珠单抗联合方案治疗铂耐药卵巢癌患者的疗效

2022-08-31

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析

2021-11-21

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗的加入让宫颈癌治疗不再“谈虎色变”

2022-03-08

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗在肺癌驱动基因阴性的治疗

2022-07-09

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-07-22

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

直肠癌转化治疗临床实战-FOLFOX+贝伐珠单抗

2022-08-27

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2022-05-24

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗治疗肺癌脑转移伴难治性瘤周水肿的不良反应

2022-08-17

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好

2022-09-15

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗

2022-08-01

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Acta Biomater：3D打印成功制备包含贝伐珠单抗和地塞米松局部递送的载药多壳棒

2021-09-18

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Thorac Oncol:阿替利珠单抗（atezolizumab）联合贝伐珠单抗+化疗一线治疗转移性非鳞状非小细胞肺癌的最终OS分析：IMpower150

2022-01-28

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

J Hepatol: Atezolizumab联合贝伐珠单抗vs索拉非尼治疗不可切除肝细胞癌的疗效更新：IMbrave150

2022-11-30

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

祝贺贝伐珠单抗在中国新增两项适应证

2021-11-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

信迪利单抗联合达攸同（贝伐珠单抗）用于一线治疗肝癌获批准

2021-12-31

科室
- - 订阅+
  - 更多科室
工具
服务